Home Search

ctxr - search results

If you're not happy with the results, please do another search

Citius Pharma (CTXR) to Merge Subsidiary, with Publicly Traded SPAC. Shares up 17%.

We Would Define This as Huge News.. Citius Pharma would receive 67.5...

Citius Pharma (CTXR). Reports Fiscal First Quarter 2023 Financial Results and Provides Business Update

$36.9 million in cash and cash equivalents as of December 31, 2022 ; runway through February 2024

Report on Citius Pharma (CTXR): North Shore Research Issues a $10 Price Target, a...

We're Up 181% on Citius Pharma (CTXR), Despite its Being Well Below it's Recent High of $4.30. We Now Have Two $10...
Biotech Stock Review

Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.

Added to Watch List November 2019 @$0.55. Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...

Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.

Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022. CITIUS NEWS ARCHIVE
@bryteeyes3

Citius (CTXR). Dang Flippers!

Short term investors powered Citius from $2.50 to near $4.50 in hopes of a positive early trial...
@NCI

Citius (CTXR) Expands Scientific Advisory Board. Dr. John Laffey, Expert in Stem Cell and...

- Addition of leading scholar and KOL in acute respiratory distress syndrome (ARDS) to ARDS Scientific Advisory Board supports continued progress of...
Issam Radd

Citius (CTXR): Halt For Superiority On The Horizon? (SeekingAlpha).

Jun. 15, 2021 10:41 AM ET Citius Pharmaceuticals, Inc. (CTXR) Summary
Biotech Stock Review. Citius, CTXR

More Great News From Citius Pharma (CTXR).

UPDATED CHART 6-15-21 Mino-Lok® Phase III, FDA NewsRussell 2000 Index NewsTechnical Breakout News

Citius Pharma (CTXR) Updates Shareholders.

Citius Update Stem Cell Study Citius Pharmaceuticals, Inc announced that it will present a poster at the International Society...

Latest article

Post Reverse Split, Tharimmune (THAR) Announces Positive Phase I Results.

This is a story of 're-purposed' FDA approved drug, from drug overdose, to a solution for unrelenting itching. If approved, it can...

Trump’s (DJT) up 48% Today

LIVE QUOTE Our only thought is it would be a great idea, to give...

Altamira Thera (CYTO) Explodes 144% Higher Post Reverse Split, With 50 Million Shares Trading...

Taking advantage of post reverse-split investor pessimism, is a VALID investing technique. Altamira is developing and supplying peptide-based...